摘要目的 对新诊断的超重/肥胖2型糖尿病(T2DM)患者进行赖脯胰岛素50联合二甲双胍的短期强化治疗,评价其疗效和安全性.方法 62例新诊断的超重/肥胖T2DM患者按机械抽样法随机分为研究组(32例)和对照组(30例),研究组予以赖脯胰岛素50联合二甲双胍治疗,对照组予以重组人胰岛素及甘精胰岛素治疗,收集疗效及安全性数据进行统计学分析.结果 两组治疗后餐前、睡前、凌晨3:00血糖比较差异无统计学意义(P＞0.05).两组血糖达标时间、低血糖发生率比较差异无统计学意义(P＞0.05).研究组胰岛素日用量及费用分别为(0.6 ±0.1) U/kg、(15.8±2.1)元/d,低于对照组的(0.8±0.1)U/kg、(21.3±2.6)元/d,差异有统计学意义(P＜0.05).结论 赖脯胰岛素50联合二甲双胍治疗为新诊断的超重/肥胖T2DM患者提供了一种快速、有效、安全的强化治疗方案,且性价比高.

abstractsObjective To evaluate the therapeutic effect and safety of insulin lispro mix 50/50 combined with mefformin in newly diagnosed overweight/obese type 2 diabetic mellitus patients.Methods Sixty-two patients with newly diagnosed overweight/obsess type 2 diabetic mellitus were randomly divided into observation group (32 cases) and control group (30 cases) by systematic sampling method.The observation group received insulin lispro mix 50/50 combined with metformin,and the control group received recombinant human insulin and insulin glargine.The therapeutic effect and safety were compared between the 2 groups.Results There were no statistical differences in the blood glucose before eating,before retiring and at mane primo 3:00 between the 2 groups (P ＞ 0.05).There were no statistical differences in the time of blood glucose standard and rate of hypoglycaemia between the 2 groups (P ＞ 0.05).Daily insulin dosage and costs in the observation group were lower than those in the control group [(0.6 ± 0.1) U/kg vs.(0.8 ± 0.1) U/kg and (15.8 ±2.1) yuan/d vs.(21.3 ±2.6) yuan/d],and there were statistical differences (P ＜0.05).Conclusion Insulin lispro mix 50/50 combined with mefformin provides a convenient,effective and safe therapy for newly diagnosed overweight/obese type 2 diabetic mellitus patients and high cost performance.